NeoGenomics (NEO) Tops Q4 EPS by 1c, Revenues Beat; Offers FY19 Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to NeoGenomics (NEO) Tops Q4 EPS by 1c, Revenues Beat; Offers FY19 Revenue Guidance

NeoGenomics Reports Record Revenue of $76 Million with 17% Organic Revenue Growth in the Fourth Quarter

February 19, 2019 7:01 AM EST

FT. MYERS, Fla., Feb. 19, 2019 (GLOBE NEWSWIRE) -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the fourth quarter and full year 2018.

Fourth Quarter 2018 Highlights:

Consolidated revenue increased 24.5% to $76.5 million Consolidated revenue increased 17.0% to $71.8 million, excluding GenoptixClinical Services revenue increased 23.3% to $65.9 million Pharma Services revenue increased 32.6% to $10.6 millionGross profit increased 38.7% to $37.1 millionGross margin increased... More